Kidney Int:肾脏纤维化发生机制研究获进展

2017-10-09 黄辛 中国科学报

复旦大学基础医学院陆利民课题组发现肾脏纤维化发生新机制,相关研究成果近日发表于《肾脏国际》杂志。


复旦大学基础医学院陆利民课题组发现肾脏纤维化发生新机制,相关研究成果近日发表于《肾脏国际》杂志。

肾脏纤维化是各种原因造成肾脏损伤进入终末期的共同特征,而肾脏纤维化的进展速度决定了肾脏功能丧失的速度,延缓肾脏纤维化进展是保护肾脏功能的关键。病理情况下TGF-活化和过度生成在肾脏纤维化发生和发展中起关键作用,但调控TGF-活化的具体机制并不清楚。

C-Myc是重要的转录因子,也被誉为细胞重编程因子之一,参与细胞表型、功能、分化状态、细胞周期等的调控。陆利民课题组的研究成果证实,病理情况下肾脏组织中C-Myc异常升高,整合素V是直接受C-Myc调控的靶基因之一,通过促进整合素V的表达,C-Myc促使细胞外基质中处于潜伏状态的TGF-被释放、活化,促进肾脏间质细胞的活化,细胞外基质蛋白过度生成和沉积,继而促进肾脏纤维化发生和发展。

研究人员发现,在肾脏纤维化发生、发展过程中,肾脏小管上皮细胞、间质细胞、系膜细胞等多种肾脏固有细胞表型和功能发生了改变,而TGF-是调控上述改变的重要因子。

原始出处:

Kidney International.October 2017Volume 92, Issue 4, Pages 888–899

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1801234, encodeId=d94f180123485, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Apr 12 11:11:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056168, encodeId=fcd62056168ff, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 17 12:11:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511310, encodeId=66b8151131042, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603082, encodeId=ea731603082d7, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1801234, encodeId=d94f180123485, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Apr 12 11:11:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056168, encodeId=fcd62056168ff, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 17 12:11:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511310, encodeId=66b8151131042, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603082, encodeId=ea731603082d7, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1801234, encodeId=d94f180123485, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Apr 12 11:11:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056168, encodeId=fcd62056168ff, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 17 12:11:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511310, encodeId=66b8151131042, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603082, encodeId=ea731603082d7, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1801234, encodeId=d94f180123485, content=<a href='/topic/show?id=d4bce344265' target=_blank style='color:#2F92EE;'>#研究获进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73442, encryptionId=d4bce344265, topicName=研究获进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Thu Apr 12 11:11:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2056168, encodeId=fcd62056168ff, content=<a href='/topic/show?id=616b611e9bc' target=_blank style='color:#2F92EE;'>#机制研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61179, encryptionId=616b611e9bc, topicName=机制研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu May 17 12:11:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511310, encodeId=66b8151131042, content=<a href='/topic/show?id=0a493e89802' target=_blank style='color:#2F92EE;'>#发生机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37898, encryptionId=0a493e89802, topicName=发生机制)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=188310331118, createdName=ms6390871039024434, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603082, encodeId=ea731603082d7, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Oct 11 07:11:00 CST 2017, time=2017-10-11, status=1, ipAttribution=)]
    2017-10-11 gwc389

相关资讯

Arch of Toxicol:清华陈立功组报道临床重要药物引起肾毒性的作用机制

唑来膦酸是第三代双膦酸盐类药物,主要通过抑制破骨细胞的活性和诱导破骨细胞凋亡来抑制骨吸收,是临床上治疗恶性高钙血症、绝经后骨质疏松、控制恶性肿瘤骨转移的重要药物,具有显着的疗效。唑来膦酸临床上常见的毒副作用为肾脏损害,尤其是肾小管损害。目前,关于唑来膦酸引起肾毒性的报道大多是其引起肾毒性的临床案例,而对其导致肾毒性的分子机制报道较少。